Jeena Sikho Lifecare Limited (JSLL) Earnings Call Transcript
November 7, 2025
Earnings Call Speaker Segments
Ladies and gentlemen, good day, and welcome to the Jeena Sikho Lifecare Limited Q2 FY '26 Earnings Conference Call. [Operator Instructions] Please note that this conference is being recorded. I now hand the conference over to Mr. Ranvir Singh from Nuvama Wealth. Thank you, and over to you, sir.
On behalf of Jeena Sikho Lifecare Limited, I extend a very warm welcome to all participants on the Q2 FY '26 financial results discussion call. Today on the call, we have Mr. Manish Grover ji, popularly known as Acharya ji, Managing Director; and Mr. Nanak Chand, CFO. Before beginning with this call, I would like to give a short disclaimer. This call may contain some of the forward-looking statements, which are completely based upon management's belief, opinion and expectations as of today. These statements are not a guarantee of company's future performance and involve unforeseen risks and uncertainties. With this, I would like to hand over the call to Acharya Manish ji for his opening remarks. Over to you, sir.
[Foreign Language]
Good afternoon, everyone. Thanks, Manish sir. As mentioned by Manish sir, we have achieved a healthy financial performance during the Q2 FY '26. Here are the key highlights. Q2 FY '26 results. So I am pleased to present before you the detailed financial performance of Jeena Sikho Lifecare Limited for quarter ended September 30, 2025, Q2 FY '26. Before we move to the details, I would like to highlight that it was the second quarter of reporting under Ind AS following our migration to main Board in August 2025. And our financial statements and disclosures are now fully aligned with the main Board standard and showing high transparency and compatibility. The company continues to maintain the strong balance sheet supported by the robust operating cash flows and prudent financial management. Now on the Q2 FY '26 performance. Revenue, our revenue grew by 66% on a Y-o-Y basis to INR 190 crores in Q2 FY '26 as product segment grew approximately 78% Y-o-Y. Service segment contributed 50% revenue during the quarter. The EBITDA during the Q2 FY '26 [ jumped over the ] 129% Y-o-Y basis to INR 92 crores by implying the EBITDA margins of 48%. The Q2 FY '26 PAT grew 121% Y-o-Y basis to INR 58.78 crores. With this, we open the floor for the question-and-answer session. Thank you.
[Operator Instructions] The first question is from the line of Akshay from AK Investment.
[Foreign Language]
[Foreign Language]
[Foreign Language]
[Foreign Language]
[Foreign Language]
[Foreign Language]
[Foreign Language]
The next question is from the line of Abhishek from AB Capital.
Am I audible?
[Foreign Language]
[Foreign Language]
[Foreign Language]
[Foreign Language]
[Foreign Language]
The next question is from the line of Ashok Parekh, an individual investor.
[Foreign Language]
[Foreign Language]
[Foreign Language]
[Foreign Language]
[Foreign Language]
[Foreign Language]
[Foreign Language]
[Foreign Language]
[Foreign Language]
[Operator Instructions] The next question is from the line of Praveen Kumar, an individual investor.
Sir, can you hear me?
[Foreign Language]
[Foreign Language] Manish ji, I was looking -- eagerly waiting to get in the call with you. Right. So many congratulations on your Q2 numbers. And I have a couple of questions, Manish ji. How is the early trend of your OTC business? First question. And my second question is, is there any revenue sharing planned with Chandan Healthcare? What's the strategy of planning there? And my last question is that do you want to update your FY '26 guidance from previously quoted INR 700 crores?
[Foreign Language]
Okay. Sir, I'm not that comfortable with Hindi, but I can understand. But I'm not -- I can't speak...
[Foreign Language]
And there was one more question on the guidance of '26. Would you like to update that?
[Foreign Language]
The next question is from the line of Gaurav Sanghvi, an individual investor.
Am I audible?
Yes. [Foreign Language]
[Foreign Language]
[Foreign Language]
[Foreign Language]
[Foreign Language]
The next question is from the line of Sainik Mehta from [indiscernible] Wealth.
[Foreign Language]
[Foreign Language]
The next question is from the line of Deepak Poddar from Sapphire Capital.
Am I audible, sir?
Yes, sir. [Foreign Language]
[Foreign Language]
[Foreign Language]
[Foreign Language]
[Foreign Language]
[Foreign Language]
[Foreign Language]
Okay. Okay. And just last final thing, [Foreign Language]
[Foreign Language]
The next question is from the line of [ Pratik Tandale ] from Code Advisors LLP.
Hello, am I audible?
Yes, sir.
[Foreign Language] Q1, we had 55. They stand at, right now?
Now, we have 58.
58. In terms of clinic, we had 61 as of Q1.
Now we have 59.
Right. And the number of beds?
And 35 franchisees.
35 franchisees. Okay. We have bed...
46, we have NABH centers now.
45 NABH. Okay.
46 NABH. And 5 are in pipeline.
46, 5 in pipeline. In terms of IPD and OPD, if you could give the updated numbers for Q2.
Sir, IPD 58 hospital [Foreign Language]
No, sir. I'm talking in terms of -- So Q1, we were at 861 -- 8,616, and OPD was 1.24 lakh. So...
[Foreign Language]
[Foreign Language]
8,616 first quarter, and 9,614 in second quarter. And total OPD volume is 1,24,364 in quarter 1. Now is 1,40,144 in quarter 2.
Okay. Perfect. And net profit margin guidance is 20% to 22%, right?
Yes, yes. Our average revenue per bed on quarter 1 is INR 8,287 and in quarter 2 is INR 8,324. Our occupancy is about same 57%.
57%. Similar as Q1, right?
Similar as Q1. If we calculate from last financial year '25 bed, it is more than 80%. Because 1,600 bed total in [ 50 ] '25. [Foreign Language]
Number of beds as of Q1 was 2,179. Am I correct?
Yes, yes. As of now is 2,220.
2,220. These are open 2,800. This is your remaining in 2 to 3 months [Foreign Language]
[Foreign Language]
Right. So the operational one as of this quarter is 22...
2,220.
The next question is from the line of Ronak Duggar, an individual investor.
[Foreign Language]
[Foreign Language]
[Foreign Language]
[Foreign Language]
[Foreign Language]
[Foreign Language]
Sorry to interrupt, Mr. Ronak. May we request you to please rejoin the queue. We have participants waiting for their turn. The next question is from the line of Amit Joshi, an individual investor.
[Foreign Language]
[Foreign Language]
[Foreign Language] 985548... [Foreign Language]
9855487770.
[Foreign Language]
[Foreign Language]
The next question is from the line of Kamal Sharma from Srishti Wealth.
[Foreign Language]
[Foreign Language]
[Foreign Language]
[Foreign Language] Nanak ji?
[Foreign Language]
[Foreign Language]
The next question is from the line of Devi Agrawal from [ Fimcom ] Family Office.
[Foreign Language]
Nanak ji?
First of all [Foreign Language]
[Foreign Language]
[Foreign Language]
[Foreign Language]
[Foreign Language] financial statement restate [Foreign Language]
[Foreign Language] Nanak ji?
Yes, sir. Yes, yes. [Foreign Language] we'll share with you.
The next question is from the line of Sanjay Nandi from VT Capital.
[Foreign Language]
[Foreign Language]
The next question is from the line of Akhilesh Rawat from [ Vedant ] Vision Private Limited.
[Foreign Language] Am I audible?
[Foreign Language]
[Foreign Language]
[Foreign Language]
[Foreign Language]
[Foreign Language]
[Foreign Language] we will go to our other part of the...
[Foreign Language]
The next question is from the line of Chirag Shah from White Pine Investment Management.
[Foreign Language]
[Foreign Language]
[Foreign Language]
[Foreign Language]
[Foreign Language]
[Foreign Language]
[Technical Difficulty]
[Foreign Language]
The next question is from the line of [indiscernible] Power.
[Foreign Language] increase our sale through e-commerce...
[Foreign Language]
[Foreign Language] regarding quick commerce like Blinkit...
[Foreign Language] Zepto, Blinkit [Foreign Language]
[Foreign Language] regarding healthcare Ease or South [Foreign Language]
The next question is from the line of Akshay from AK Investment.
[Foreign Language]
[Foreign Language]
Ladies and gentlemen, that was the last question for today. I would now like to hand the conference over to the management for closing comments.
[Foreign Language]
No, sir. It is like handed over to you for closing comments.
Okay. Okay. [Foreign Language]
Thank you. On behalf of Nuvama Wealth and Investment Limited, that concludes this conference. Thank you for joining us, and you may now disconnect your lines.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Jeena Sikho Lifecare Limited transcript - plus 252,000+ transcripts from 12,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Jeena Sikho Lifecare Limited earnings transcripts and 252,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $105 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.